RAPP
HealthcareRapport Therapeutics, Inc. Common Stock
Key Drivers
- Cash Resilience
- Revenue Emergence
- Deep Losses
AIAI Summary
RAPP has moved from a speculative early-stage biotech to a multi-catalyst clinical story, with strong liquidity and a runway to 2029, but the investment still hinges on RAP-219 converting Phase 2a promise into successful Phase 3 execution and the Q4 2026 bipolar readout delivering proof before the rich valuation gets harder to justify.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Resilience
- •Revenue Emergence
- •Deep Losses
RAPP has a strong cash-rich, low-debt balance sheet and has begun generating revenue, but persistent losses, negative cash flow, and a rich valuation keep the equity risky.
Price Behavior
Key Price Behavior Insights:
- •Rally Rejected
- •Support Holding
- •Neutral Momentum
RAPP's trend over the last month is mildly positive but uneven, as a sharp rally to $41.67 faded back toward the $38 support zone, leaving momentum neutral and requiring a break above $41.70 to regain strength.
Sharp rally to $41.67 reversed back toward $38.97, signaling short-term profit-taking
Sentiment & News
Key News Insights:
- •Conference presence
- •No new catalysts
- •Routine disclosure
Rapport Therapeutics' latest update was limited to a conference presentation and transcript release, signaling routine investor communications rather than any new operational, clinical, or financial catalyst.
This appears neutral for the stock, as it reinforces visibility but does not change the company's fundamental outlook
Similar Companies in Healthcare
Other companies in the same sector with AI ratings